Aslan Pharmaceuticals Ltd
Change company Symbol lookup
Select an option...
ASLN Aslan Pharmaceuticals Ltd
NXPI NXP Semiconductors NV
PRTK Paratek Pharmaceuticals Inc
VTR Ventas Inc
GBIM Globeimmune Inc
SCKT Socket Mobile Inc
BK Bank of New York Mellon Corp
BAC Bank of America Corp
AACG ATA Creativity Global
MDXL Medixall Group Inc
Go

Health Care : Biotechnology |
Based in Singapore
Company profile

ASLAN Pharmaceuticals Limited (ASLAN) is a clinical-stage immunology and oncology-focused biopharmaceutical company. ASLAN has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$1.91
Day's Change
-0.14 (-6.83%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.97
Day's Low
1.83
Volume
(Heavy Day)

Today's volume of 460,512 shares is on pace to be much greater than ASLN's 10-day average volume of 963,942 shares.

460,512
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.